DermTech (DMTX) is - at the time of writing - a $131m market cap medical technology company that describes itself as follows in its 2022 10-K Submission (annual report). We are a molecular diagnostic ...
SAN DIEGO, March 26, 2026 /PRNewswire/ -- DermTech 2.0 ("DermTech LLC" or "The Company"), a leader in precision dermatology enabled by DermTech's proprietary non-invasive Smart Sticker ® skin sample ...
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you pick the right stock, you can make a lot more than 100%. For example, the DermTech, Inc.
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that ...
DermTech is harnessing the power of Precision Dermatology to eradicate death from skin cancer. Precision Dermatology works extremely well in detecting early stage of the deadly skin cancer, melanoma.
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the topline results ...
DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced additional restructuring actions to ...
Constellation Alpha Capital Corp. Announces Successful Closing of Business Combination With DermTech
Combined Company will trade on the Nasdaq Capital Market under “DMTK” DermTech’s flagship product, the Pigmented Lesion Assay (PLA), enables non-invasive and early detection of melanoma using genomic ...
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications ...
DermTech (NASDAQ: DMTK) is trying to redefine the process for identifying skin cancer. The current approach involves a visual inspection and an invasive biopsy -- a highly inaccurate method that most ...
DermTech Inc DMTK shares were soaring to a new high Thursday after the company unveiled a contract with Blue Cross Blue Shield of Texas for its melanoma gene express test. What Happened: La Jolla, ...
Firm Retention Summary: DermTech This is a summary of a request from the Official Committee of Unsecured Creditors of DermTech to hire Potter Anderson & Corroon as Delaware counsel, filed July 24 with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results